|
所属 |
医学部 附属病院 麻酔科 |
|
職名 |
助教 |
|
外部リンク |
|
|
関連SDGs |
|
論文 【 表示 ／ 非表示 】
-
與那覇 哲, 丸田 豊明, 太田尾 剛, 矢野 武志, 谷口 正彦, 北村 和雄, 恒吉 勇男
Anaesthesiology Intensive Therapy 53 ( 5 ) 411 - 417 2021年12月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Termedia
Background: Information about biologically active adrenomedullin (mature AM), a potential new biomarker for sepsis and septic shock, is limited. Here, we investigated the value of mature AM for diagnosis and outcome prediction in sepsis.
Methods: Patients admitted to the intensive care unit (ICU) were retrospectively categorised into non-sepsis or sepsis groups, according to the Sepsis-3 definitions. Plasma levels of mature and total (the sum of the levels of intermediate and mature forms) AM were measured, and their usefulness was compared with that of other sepsis biomarkers, such as procalcitonin and presepsin.
Results: Of the 98 patients analysed, 42 were assigned to the non-sepsis and 56 to the sepsis group. Mature and total AM levels on admission were significantly higher in patients with than in those without sepsis. The areas under the receiver operating characteristic curves (AUCs) of mature and total AM for diagnosing sepsis were 0.85 and 0.88, whereas those of procalcitonin and presepsin were 0.83 and 0.68, respectively. AUCs of mature and total AM for predicting 28-day mortality in patients with sepsis became significant on day 3 after admission. A good correlation between the AM forms was found, indicating that changes in their plasma levels may directly reflect each other.
Conclusions: Because mature and total AM levels increased significantly in patients with sepsis on admission, both forms may be used as reliable and early biomarkers for diagnosing sepsis according to the Sepsis-3 definitions. However, prediction of 28-day mortality in such patients would require several days of ICU stay. -
太田尾 剛, 丸田 豊明, 與那覇 哲, 北村 和雄, 恒吉 勇男
Journal of Clinical and Translational Research 7 ( 3 ) 302 - 310 2021年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Whioce
Background and aim: Adrenomedullin (AM), a vasodilatory peptide, is known for its pleiotropic actions. AM levels are increased under inflammatory conditions such as sepsis and can be useful as a prognostic biomarker. However, there are only a few reports on the physiological actions of AM in the perioperative period. The aim of this single-center, prospective, observational study was to investigate the changes in the plasma levels of mature AM (mAM) and total AM (tAM) observed during the perioperative period. Additionally, we aimed to determine the association between each AM level and immune-inflammatory parameters to explore the usefulness of AM as a biomarker of the magnitude of surgical stress responses.
Methods: The levels of both mAM and tAM, in addition to the levels of presepsin, interleukin-6, procalcitonin, white blood cell, and C-reactive protein, were measured in blood samples obtained during the perioperative period. Other laboratory data, including sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation (APACHE) II scores, were obtained from individual clinical records. Correlations between each AM and clinical parameters were determined using Spearman's rank correlation. P-values < 0.05 were considered statistically significant.
Results: One-hundred and twenty-three perioperative patients scheduled for three types of surgical procedures, including cardiopulmonary bypass surgery, abdominal surgery, and cervical laminoplasty, were included in this study. There was a moderate to strong correlation between each AM and immune-inflammatory parameters, SOFA score, and APACHE II score, as related to surgical trauma. Specifically, the strongest correlation was observed between each AM and SOFA score.
Conclusions: These findings suggest that plasma AM levels may represent the most important inflammatory mediators that are evident in surgical stress responses.
Relevance for patients: Since the levels of both tAM and mAM show the same trend, mAM and tAM may be equally used as biomarkers for the evaluation of the physiological status of surgical patients.
Trial registration: This observational study was retrospectively registered with Japanese Clinical Trial Registry “UMIN-CTR” on March 19, 2018, and was given a trial ID number UMIN000031792. -
丸田 豊明, 太田 尾剛, 与那覇 哲, 北村 和雄, 恒吉 勇男
循環制御 39 ( 3 ) 169 - 171 2019年1月
記述言語：日本語 掲載種別：研究論文（学術雑誌） 出版者・発行元：日本循環制御医学会
DOI： 10.11312/ccm.39.169
-
周術期における目標指向型治療 (Goal-directed Therapy) の有効性 (誌上抄読会) 査読あり
丸田豊明, 太田尾剛, 宮里岳志, 新福玄二, 山下幸貴, 森信一郎, 河野太郎, 白阪哲朗, 指宿昌一郎, 谷口正彦, 恒吉勇男
臨床麻酔 41 ( 6 ) 897 - 902 2017年6月
記述言語：日本語 掲載種別：研究論文（学術雑誌）
-
Effects of intravenous low-dose recombinant human atrial natriuretic peptide on renal function in the perioperative management for gastrointestinal perforation or ileus: A retrospective single-center study. 査読あり
Toyoaki Maruta, Go Otao, Takeshi Miyazato, Nozomi Maruta, Koichiro Yamauchi, Takao Yano, Taro Kawano, Isao Tsuneyoshi
Journal of critical care 28 ( 2 ) 133 - 140 2013年4月
記述言語：英語 掲載種別：研究論文（学術雑誌）
講演・口頭発表等 【 表示 ／ 非表示 】
-
敗血症における血漿アドレノメデュリンの時間的推移
與那覇 哲，太田尾 剛，丸田豊明，矢野武志，白阪哲朗，恒吉勇男
第40回日本循環制御医学会総会 (軽井沢) 日本循環制御医学会
開催年月日： 2019年6月7日 - 2019年6月8日
記述言語：日本語 会議種別：口頭発表（一般）
開催地：軽井沢
-
Adrenomedullin as a perioperative biomarker: the correlation between inflammatory/ infectious parameters and sequential organ failure assessment/ acute physiology and chronic health evaluation Ⅱ scores in surgical patients. 国際会議
Go Otao, Toyoaki Maruta, tetsu Yonaha, Sayaka Nagata, Kazuo Kitamura, Isao Tsuneyoshi
2018 Annual Meeting, American Society of Anesthesiologists (San Francisco) American Society of Anesthesiologists
開催年月日： 2018年10月13日 - 2018年10月17日
記述言語：英語 会議種別：ポスター発表
開催地：San Francisco
-
周術期バイオマーカーとしてのアドレノメデュリン 招待あり
丸田豊明，太田尾 剛，與那覇 哲，北村和雄, 恒吉 勇男
第39回日本循環制御医学会総会 (宮崎) 日本循環制御医学会
開催年月日： 2018年6月1日 - 2018年6月2日
記述言語：日本語 会議種別：シンポジウム・ワークショップ パネル（指名）
開催地：宮崎
-
TOFCuffの使用経験 TOFWatchとの比較検討．
児玉芳史, 佐藤文明, 君安貴寛, 太田尾 剛, 恒吉勇男
日本臨床麻酔学会第37回大会 (東京) 日本臨床麻酔学会
開催年月日： 2017年11月3日 - 2017年11月5日
記述言語：日本語 会議種別：ポスター発表
開催地：東京
-
大量出血、産褥期心筋症により術中心停止した帝王切開患者を部分体外循環使用により救命し得た一例．
溜渕昌美, 深尾麻由, 太田尾 剛, 森 信一郎, 恒吉勇男
日本臨床麻酔学会第37回大会 (東京) 日本臨床麻酔学会
開催年月日： 2017年11月3日 - 2017年11月5日
記述言語：日本語 会議種別：ポスター発表
開催地：東京